Toggle Contrast

Ricki Ostrov, Author at RM Partners - Page 3 of 6

New year education event on pharmacy oncology

The RM Partners Medicines Optimisation group is hosting the second pan-London education evening on Wednesday 16 January 2019, with a focus on ‘ESMO...
Read full story

Bowel screening reminder service a success

The RM Partners pilot to increase uptake bowel screening across south west London has proven incredibly successful. All six CCGs in the area took...
Read full story

Celebrating our impact and achievements

The RM Partners Annual Review, which celebrates our transformational cancer work across west London, has now been published. The review contains a...
Read full story

Lung health checks benefitting hundreds of west Londoners

Over 500 people in Hillingdon and Hammersmith and Fulham have already participated in the RM Partners pilot project to help pick up lung cancer...
Read full story

RAPID wins HSJ award for innovation

Our RAPID (Rapid Access to Prostate Imaging and Diagnosis) project won the prestigious HSJ Award for Acute Sector Innovation 2018 from a strong...
Read full story

Social media campaign to increase cervical screening uptake

RM Partners, in partnership with the Hammersmith and Fulham GP Federation, is running a social media campaign to raise awareness of a new service...
Read full story

Helping GPs improve skin cancer diagnoses in Sutton

RM Partners is supporting a small pilot project in Sutton to help GPs learn to better identify suspicious skin lesions and increase appropriate...
Read full story

Sharing learning about our RAPID prostate pathway

RM Partners held the first RAPID prostate pathway network meeting to share data, look at the similarities and differences of the three pilot...
Read full story

AI helping GPs identify possible cancers earlier

RM Partners has just launched a pilot in Sutton that uses an award winning AI decision support tool, C the Signs, to help GPs identify patients at...
Read full story

New patient information leaflet on biosimilar trastuzumab

The second cancer biosimilar, trastuzumab, has been approved to treat patients with HER2-positive early breast cancer, metastatic breast cancer, and...
Read full story